AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win

Phase 3positiveQuliptaPositive

AI Analysis

Summary

AbbVie announced positive Phase III LUNA trial results for Qulipta in menstrual migraine, an indication without specifically approved therapies, and plans to submit data to global regulators.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Phase III LUNA trial showed positive results in menstrual migraine indication

Importance:7/10

Sentiment:

0.70

Phase III datamigrainemenstrual migraineregulatory submissionQuliptaindication expansion

Related Companies

$ABBV

Read the original article

Published by Clinical Trials Arena on September 11, 2026 11:02 AM

Read Original